Anti-Fungal Agents Market is Set to Experience a Revolutionary Growth by 2027
Market Analysis
The global antifungal treatment
market is predicted to touch USD 19,558.0 million at a 4.61% CAGR over the
forecast period (2017-2023), states the latest Market Research Future (MRFR)
report. Fungal infections in the body result from unclean and unhygienic
environments where fungal agents thrive. Such agents grow by spreading spores,
which causes skin infection subsequently or when fungal infections are inhaled
(systematic). Antifungal drugs or treatment are substances that selectively
acts against the fungal pathogen in the fungal infection treatment.
Allylamines, polyenes, echinocandins, pyrimidines, and azoles are the most
widely used antifungal treatments.
Various factors are propelling the antifungal
treatment market growth. Some of these factors, according to the Market
Research Future report, include rising number of patients with fungal diseases,
rising geriatric population, growing awareness regarding different fungal
infections, rising corporate and government initiatives, and rise in population
which come in contact with infections and resistant fungal strains. Additional
factors pushing market growth include the weakened immune system, rising
disposable income, increased investments in research and development
activities, private-public partnership agreements in the pharmaceutical sector
to develop new and effective antifungal drugs, and growing demand for over the
counter (OTC) drugs to treat skin infections.
On the contrary, availability of
conventional therapies and generic drugs for fungal infections, allergic
reaction to specific antifungal drugs, and government regulations in the
pharmaceutical industry are factors that may deter the antifungal treatment
market growth over the forecast period.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/2582
Key Players
Leading players profiled in the
antifungal treatment market report include Bayer AG (Germany), Astellas
(Japan), Merck & Co., Inc. (U.S), Sanofi (France), Pfizer Inc. (U.S), and
Novartis AG (Switzerland), among others. Key players have incorporated
strategies such as technology launch, expansion, partnership, collaboration,
and acquisition for gaining a competitive advantage in the market.
Market Segmentation
The MRFR report offers a wide
segmental analysis of the antifungal treatment market on the basis of drug
class, therapeutic indication, pathogen, and end users.
Based on drug class, the antifungal treatment market is segmented into
allylamines, polyenes, echinocandins, pyrimidines, azoles, and others. Of
these, the azoles segment will have the largest share in the market over the
forecast period. Azoles are used for treating ocular fungal infections,
systemic candidiasis, blastomycosis, and candidemia.
Based on therapeutic indication, the antifungal treatment market is segmented into
cryptococcosis, coccidioidomycosis, candidiasis, and systemic. Of these, the
systemic segment will dominate the market over the forecast period.
Based on pathogens, the antifungal treatment market is segmented into
trichophyton, zygomycetes, coccidioides immitis, cryptococcus, aspergillus,
candida, and others.
Based on end user, the antifungal treatment market is segmented into
dermatology clinics, hospitals and clinics, and others.
Regional Analysis
By region, the antifungal treatment
market report covers the latest trends and growth opportunities across the
Americas, the Asia Pacific, Europe, and the Middle East and Africa. Of these,
the Americas, particularly North America, will lead the market over the
forecast period. This is owing to the rising incidences of patients in this
region with fungal infections, developed healthcare infrastructure, and quick
adoption of new antifungal treatments.
The antifungal treatment market in
Europe will have the second-largest share in the market over the forecast
period. Most companies in Europe are emphasizing on R&D of antifungal drugs
that in turn, is pushing market growth. These companies are getting government
funding that is favoring the market growth in this region.
The antifungal treatment market in
the APAC region is predicted to grow at the fastest pace over the forecast
period. This is owing to the increasing awareness regarding available fungal
infection treatments, rising healthcare expenditure, rising adoption of new
medical practices, and developing healthcare infrastructure.
The antifungal treatment market in
the Middle East and Africa is predicted to have a slow growth over the forecast
period. This is owing to limited access to healthcare facilities and lack of
awareness regarding antifungal treatments.
March 2019: Pharmbio Korea has signed
a deal with BioSynectics for creating an antifungal treatment, PBK-1819-2. The
company will use the nanotechnology of BioSynectics to create the drug. The
nano-conversion technology will offer an array of perks such as lower side
effects, dietary as well as post-diastolic deviation, and improved
bioavailability.
Access Report Details @ https://www.marketresearchfuture.com/reports/mea-anti-fungal-agents-market-2582
Related Report: Dysmenorrhea
Treatment Market Research Report- Global Forecast to 2027
Syringe
and Needle Market Research Report - Global Forecast to 2027
Global
Medical Robotics Market Research Report- Forecast To 2027
Global
Neuromodulation Devices Market Research Report- Forecast To 2027
Global
Erythropoietin Drug Market Research Report- Forecast To 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment